Drug Trial Radar · NCT06840392
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
565
Actual
Start
Mar 20, 2025
Primary completion
Jun 3, 2027
Study completion Oct 21, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Conditions
- Hidradenitis Suppurativa
Interventions
Remibrutinib Dose ADrug
Remibrutinib Dose A (oral)
Remibrutinib Dose BDrug
Remibrutinib Dose B (oral)
Placebo 1Drug
Placebo matching to remibrutinib Dose A (oral)
Placebo 2Drug
Placebo matching to remibrutinib Dose B (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16Time frame: Week 16
Locations
129 sites in 19 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center PC
Birmingham, Alabama
CTT Research
Gilbert, Arizona
Ctr for Dermatology Clinical Res
Fremont, California
USC Keck School of Medicine
Los Angeles, California
MedDerm Associates
San Diego, California
Driven Research
Miami, Florida
Floridian Research Institute
Miami, Florida
Sarasota Arthritis Res Ctr
Sarasota, Florida
University Of South Florida
Tampa, Florida
Emory School of Med Dermatology
Atlanta, Georgia
Atlanta Biomedical Clin Res LLC
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Endeavor Health
Glenview, Illinois
Dundee Dermatology
West Dundee, Illinois
Southern IN Clinical Trials
New Albany, Indiana
Beth Israel Deaconess Med Center
Boston, Massachusetts
Metro Boston Clinical Partners
Brighton, Massachusetts
Clinical Research Inst of MI
Chesterfield, Michigan
Deluxe Dermatology
St Louis, Missouri
Skin Specialists PC
Omaha, Nebraska
Vivida Dermatology
Las Vegas, Nevada
North Shore University Hospital
New Hyde Park, New York
Cameron Dermatology
New York, New York
Optima Research Boardman
Boardman, Ohio
Ohio State University
Columbus, Ohio
Wright State University
Fairborn, Ohio
Apex Clinical Research Center LLC
Mayfield Heights, Ohio
Clinical Research Ctr of Carolinas
Charleston, South Carolina
Goodlettsville Dermatology Research
Goodlettsville, Tennessee
Accurate Clinical Research
Humble, Texas
Austin Inst for Clinical Research
Pflugerville, Texas
Center for Clinical Studies-Lee
Webster, Texas
Care Access Alexandria
Arlington, Virginia
Complexions Dermatology
Danville, Virginia
Forefront Dermatology
Vienna, Virginia
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Liège, Belgium
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.